No Disruption in Supply as Recordati Takes Over Sales of Signifor

Written on .

The Cushing’s drugs Signofor and Signifor LAR are now going to be marketed in the U.S. by Recordati, which purchased the rights from Novartis last year. The company says there will be no disruption in supply and the new company will offer a program to subsidize the drugs for low-income families. Read the article here: https://cushingsdiseasenews.com/2020/03/03/recordati-rare-diseases-will-market-signifor-signifor-lar-in-u-s/

Print